Abstract:OBJECTIVES A systematic review and meta-analysis based on randomized controlled trials (RCTs) of the efficacy and safety of daptomycin versus comparators. METHODS Electronic databases (PubMed, Embase, Cochrane Central Register of Controlled Trials and clinical registered trials) were searched to identify RCTs that assessed the efficacy and safety of daptomycin versus therapy with comparators. Two reviewers independently applied selection criteria, performed a quality assessment and extracted the data. The I(2) statistic was calculated for heterogeneity, and a random-effects or fixed-effects model was used for estimates of risk ratio (RR). The primary outcome assessed was clinical treatment success among the intention-to-treat (ITT) population. RESULTS Thirteen trials fulfilled the inclusion criteria. Daptomycin was as efficacious as comparator regimens among the ITT population (RR = 0.98, 95% CI 0.93-1.03) but had a lower efficacy among the clinically evaluable (CE) population (RR = 0.96, 95% CI 0.93-1.00). Subgroup analyses according to the quality of the trial, the type of antibiotic and the type of infection did not alter the outcomes. No significant difference was identified for all-cause mortality between the daptomycin and comparator groups (RR = 1.17, 95% CI 0.76-1.79) but daptomycin therapy did reduce the duration of treatment. Daptomycin caused a significantly lower incidence of renal impairment, nausea and headache but caused a reversible increase in creatine phosphokinase (CPK). Subgroup analysis indicated that daptomycin was significantly associated with a higher incidence of CPK elevation and fewer renal impairments among the population with a mean age ≤60 years and a dose of daptomycin ≥6 mg/kg/24 h. CONCLUSIONS Daptomycin showed efficacy similar to the comparator regimens among the ITT population but lower efficacy among the CE population. Fewer adverse effects in total, but more CPK elevation effects, were observed in patients treated with daptomycin.

Study on domestic literature analysis of adverse drug reactions caused by daptomycin

The domestic literature analysis of adverse drug reactions caused by triazole antifungal drugs

Study on 990 Cases of Adverse Drug Reaction

Analysis of Adverse Drug Reactions Caused by Vancomycin and Norvancomycin

Analysis of the Adverse Drug Reactions Reports of 139 Cases

Analysis of 136 ADRs Induced by Chinese Patent Medicine

Analysis of 1785 ADR Cases Reported in Our Hospital

[The Efficacy and Safety of Daptomycin for the Treatment of Gram-positive Bacterial Infections in Chinese Population].

Analysis on 342 Repors and Discssion about the Methods of Prevention with Adverse Drug Reactions/events

Analysis on 522 cases of antibacterial-related adverse drug reaction/event reports

Analysis of 41 adverse drug reactions

Analysis on Adverse Drug Reactions in Our Hospital from 2008 to 2010

Analysis of 172 Samples Reported and Discussion about the Methods of Prevention with Adverse Drug Reactions

2008-2011 Adverse Drug Reaction Analysis of 490 Cases in Huadong Hospital

Clinical analysis of adverse drug reactions occurred to 630 cases from 2008 to 2010.

Analysis of 114 Severe ADR Cases Induced by Antibacterial Drugs in Our Hospital

Efficacy and Safety of Daptomycin for the Treatment of Infectious Disease: a Meta-Analysis Based on Randomized Controlled Trials.

Analysis of 203 reports on adverse reaction in our hospital

A Retrospective Study on 990 ADR Case Reports in Our Hospital During 2002～2005

Analysis on 115 Cases of ADR Reports in Our Hospital

Analysis of adverse reactions/adverse events induced by etimicin in Beijing medical institutions